Ajanta Pharma Limited Share Price Bombay S.E.

Equities

AJANTPHARM

INE031B01049

Pharmaceuticals

Market Closed - Bombay S.E. 11:00:48 10/05/2024 BST 5-day change 1st Jan Change
2,376 INR -1.42% Intraday chart for Ajanta Pharma Limited +6.39% +13.98%

Financials

Sales 2024 42.09B 504M 40.21B Sales 2025 * 47.29B 566M 45.18B Capitalization 297B 3.55B 284B
Net income 2024 8.16B 97.72M 7.8B Net income 2025 * 9.46B 113M 9.04B EV / Sales 2024 6.67 x
Net cash position 2024 * 7.97B 95.44M 7.62B Net cash position 2025 * 8.39B 100M 8.01B EV / Sales 2025 * 6.1 x
P/E ratio 2024
34.4 x
P/E ratio 2025 *
31.8 x
Employees 7,713
Yield 2024 *
0.85%
Yield 2025 *
0.76%
Free-Float 50.31%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.42%
1 week+6.39%
Current month+7.12%
1 month+10.48%
3 months+9.86%
6 months+26.77%
Current year+13.98%
More quotes
1 week
2 327.85
Extreme 2327.85
2 454.95
1 month
2 049.75
Extreme 2049.75
2 531.95
Current year
2 003.55
Extreme 2003.55
2 531.95
1 year
1 240.55
Extreme 1240.55
2 531.95
3 years
1 062.20
Extreme 1062.2
2 531.95
5 years
560.00
Extreme 560
2 531.95
10 years
266.67
Extreme 266.6667
2 531.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 31/12/98
Chief Executive Officer 52 31/12/95
Director of Finance/CFO 59 22/04/98
Members of the board TitleAgeSince
Chief Executive Officer 52 31/12/95
Chairman 77 30/12/79
Director/Board Member 78 19/10/08
More insiders
Date Price Change Volume
10/05/24 2,376 -1.42% 11 315
09/05/24 2,410 +1.82% 5,116
08/05/24 2,367 -1.32% 11,304
07/05/24 2,399 -0.68% 17,241
06/05/24 2,415 +1.60% 9,833

Delayed Quote Bombay S.E., May 10, 2024 at 11:00 am

More quotes
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2,377 INR
Average target price
2,440 INR
Spread / Average Target
+2.64%
Consensus